US pharma giant Pfizer and Hertfordshire-based drug company Flynn Pharma abused their market dominance by charging “excessive and unfair prices” for an anti-epilepsy drug, Britain’s competition watchdog has said. Following a comprehensive investigation, the Competition and Markets Authority (CMA) released a scathing statement on Thursday suggesting the two pharma firms may have breached UK and...